● pepmg Research Desk · Peer-reviewed evidence review
What the research says about BAM15
A neutral summary of the peer-reviewed literature on BAM15, a mitochondrial-uncoupler small molecule studied in cell and animal models of obesity and metabolic disease. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- BAM15 is a small-molecule mitochondrial uncoupler (a protonophore) that dissipates the mitochondrial proton gradient, increasing energy expenditure without, in animal studies, reducing food intake [1][6].
- The evidence is preclinical: BAM15 has been studied in mice and cell systems for diet-induced obesity, insulin resistance, sarcopenic obesity, and fatty liver, with no controlled human trials [1][2][3].
- One human cell study found that BAM15 impaired sperm motility, illustrating that its mitochondrial effects extend beyond fat tissue [6].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What BAM15 is
BAM15 is described in the literature as a selective, mitochondrially targeted small-molecule uncoupler (protonophore) that disrupts the coupling between electron transport and ATP synthesis, so cells burn more nutrients as heat and expend more energy [5][2]. A review summarizes its proposed mechanism and the diseases in which it has been explored preclinically, including obesity, diabetes, and fatty-liver disease [5].
It is sold as a research chemical. This page summarizes the published preclinical research; material from third-party vendors is offered for laboratory and research use only and is not a medicine for any condition.
What the preclinical research has measured
Preclinical onlyThe metabolic work is in mice and cells. In a study in mice, BAM15 was orally bioavailable and decreased body-fat mass without altering food intake, lean body mass, or body temperature, while reducing hepatic fat and improving insulin sensitivity in clamp studies [1]. A separate study reported that BAM15 stimulated energy expenditure and protected mice against diet-induced obesity, with improved body composition and glycemic control that were, in part, independent of weight loss [2].
In an 80-week-old mouse model of sarcopenic obesity, BAM15 decreased body weight and increased measures of muscle mass, strength, and locomotor activity, effects the authors linked to improved mitochondrial quality control and reduced muscle inflammation [3]. A head-to-head comparison in a severe-metabolic-disease mouse model reported that BAM15 improved body weight and liver steatosis to a degree comparable with or better than semaglutide, rosiglitazone, and calorie restriction, though it noted no single agent corrected every facet of the disease [4].
Across this literature there are no controlled human efficacy trials. The obesity context is often framed with epidemiology (obesity affects more than 40% of US adults and about 13% of the global population), but the BAM15 experiments themselves are preclinical [1].
What the studies report on safety and adverse events
Preclinical onlyBecause the BAM15 research summarized here is preclinical, there is no controlled human safety dataset. In mice, one study reported that BAM15 decreased body fat without changing body temperature or standard biochemical and haematological markers of toxicity [1], and a review characterized its safety profile in animal work as encouraging with minimal adverse effects, while flagging formulation and delivery challenges [5].
A counterpoint comes from human-cell work: a study of human spermatozoa found that BAM15 specifically uncoupled sperm mitochondria and significantly decreased progressive sperm motility, though without reducing overall ATP content, because the cells could rely on glycolysis [6]. This illustrates that BAM15's mitochondrial effects are not confined to fat tissue.
No human safety conclusions can be drawn from this evidence base. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence is characterized as preclinical: BAM15's metabolic effects have been measured in mice and cell systems, with no controlled human trials in this evidence base [1][2][3]. "Preclinical" describes where the research sits, not a verdict that BAM15 does or does not work in people, and mitochondrial uncouplers as a class have a long, cautionary history in humans.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 6
- Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice.
- BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control.
- Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control.
- Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
- BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases.
- Mitochondrial uncouplers impair human sperm motility without altering ATP content.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.